A patient who is taking beta blockers is monitored for shock. Which manifestation of the shock won't present… - KPSC Staff Nurse - 2018

KPSC Staff Nurse - 2018

Medical & Surgical Nursing

Medium

Appeared in: KPSC Staff Nurse - 2018

Explanation

Tachycardia.
Shock triggers a sympathetic nervous system response, which normally causes the heart rate to increase (tachycardia) to compensate for low blood pressure.
Beta-blockers work by blocking beta-1 adrenergic receptors in the heart, which are responsible for increasing heart rate.
By blocking these receptors, beta-blockers prevent or 'blunt' the expected tachycardic response to shock.
Therefore, a patient on beta-blockers may have a normal or even slow heart rate despite being in a state of shock, making tachycardia the manifestation that won't present.

Option A: Hypotension (low blood pressure) is a fundamental characteristic of shock, resulting from inadequate circulatory volume or function. Beta-blockers do not prevent hypotension; in fact, by preventing a compensatory heart rate increase, they can sometimes worsen it.
Option C: Oliguria (low urine output) is a sign of decreased perfusion to the kidneys, which is a consequence of the low blood pressure and systemic vasoconstriction seen in shock. Beta-blockers do not prevent this end-organ manifestation.
Option D: Altered mental status (e.g., confusion, lethargy) results from decreased blood flow and oxygen delivery to the brain. This is a sign of severe shock and end-organ hypoperfusion, which is not prevented by beta-blockers.

Clinical Relevance

Nursing practice connection: Prioritize focused assessment, early escalation, and real-time monitoring when managing The effect of beta-blocker medication on the clinical manifestations of shock in acute care settings.
Nurses must maintain a high index of suspicion for shock in patients on beta-blockers, as the most common early warning sign (tachycardia) will be absent.
Monitoring in these patients should focus on trends in blood pressure (especially Mean Arterial Pressure - MAP), urine output (less than 0.5 mL/kg/hr is a red flag), mental status, and skin perfusion (capillary refill, temperature).
What if the patient was in neurogenic shock? In neurogenic shock, there is a loss of sympathetic tone, which can also lead to the absence of tachycardia (and often causes bradycardia) along with hypotension. The presence of a beta-blocker would further compound this effect.

How to Approach the Question

First, identify the core concepts in the question: 'beta blockers' and 'shock'.
Recall the normal physiological response to shock: the sympathetic nervous system causes tachycardia, vasoconstriction, etc., to compensate for low blood pressure.
Next, recall the mechanism of action of beta-blockers: they block beta-adrenergic receptors, primarily in the heart.
Connect these two concepts: How would a drug that blocks the heart's response to sympathetic stimulation affect the signs of shock?
Evaluate each option: Tachycardia is a direct result of sympathetic stimulation on the heart, so it will be blocked. Hypotension, oliguria, and altered mental status are consequences of poor perfusion, which are not prevented by beta-blockers. Therefore, tachycardia is the sign that won't present.

Concept Tested & Keywords

Concept Tested: The effect of beta-blocker medication on the clinical manifestations of shock.
Stem keywords: beta blockers, shock, manifestation
Lead-in keywords: won't present
Clinical cues: Patient is on a specific medication class (beta-blockers) that alters typical physiological responses.
Negative lead-in flag: The question asks which sign 'won't present', requiring identification of the masked symptom.

QrsNo3FhCaJEMD8x3_L9yo

E6 Medicine Harrison 22e Part 2 p. 216-218